BioGenCell

Company Overview

Snapshot

Founded in December 2008 by Yael Porat, Eyal Peleg, and Michael Belkin, BioGenCell operates with 11–50 employees. The company has raised $18.35 million across four funding rounds. In May 2022, BioGenCell secured a Seed round led by Marius Nacht to advance its microvascular disease treatments.

Business overview

BioGenCell is a Health Tech & Life Sciences company focused on developing cellular therapies for degenerative diseases, particularly those involving blood flow problems in the limbs, often associated with diabetes and heart disease. The company's core technology involves creating autologous cells, derived from patients themselves, to facilitate self-repair. Its lead product, BC1, targets blood vessel insufficiency in diabetic patients, aiming to regenerate damaged tissues. BioGenCell's patented platform supports rapid manufacturing and long-term storage of therapeutic cellular products, with the broader goal of addressing conditions such as heart failure, stroke, blindness, cancer, and immunological diseases.

Strategic signal

In July 2024, BioGenCell was highlighted for pioneering revolutionary cell therapy for microvascular disease. This signals significant progress in the company's clinical development and validates its innovative approach to regenerative medicine, indicating potential for impactful advancements in treating complex degenerative conditions.

Company Intelligence Q&A

What was a significant recent regulatory milestone for BioGenCell?

In December 2024, BioGenCell received FDA Fast Track Designation with Expanded Access for its product BGC101, signaling accelerated development and potential for earlier patient access to its regenerative medicine therapy.

When did BioGenCell secure its most recent funding round?

In May 2022, BioGenCell raised a Seed round, with Marius Nacht as a lead investor, to further develop its treatments for microvascular diseases.

What is BioGenCell's primary product?

BioGenCell's lead product, BC1 (also referred to as BGC101), is designed to treat blood vessel insufficiency, which can lead to multiple organ failure in diabetic patients, by using autologous stem cells.

Has BioGenCell received any grants?

In May 2019, BioGenCell received a grant from the Service Public of Wallonia, DGO6.

When did BioGenCell present its initial human trial results?

In May 2020, BioGenCell presented promising results from its first-in-human study, indicating progress in its clinical development.